Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Ad26.RSV.preF in RSV-Seronegative Toddlers
NCT03606512Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Nov 2021
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Jan 2019; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03606512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606512.